George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Are you going around posting on all stock pages that don't sell non-essential products?! This being 99.9% of aim companies. Your comments don't help...lots of people sitting on big paper losses that don't need to read those pointless comments.
IDP has a robust balance sheet & strength in key financial areas which will see us through the next couple of 'tough' months;
- HIgh Stock level (Cash Positive)
- High level debtors, strongly outweighing creditors (Cash Positive)
- Low Fixed Costs
- Great DTC channel that will generate instant revenue/cash
- No Debt/ No Loan interest
Most AIM companies will struggle to have 1 or 2 elements of the above. Easy to forget what we have at IDP!!
https://eddiestobart.com/news-and-insights/toogood-international-joins-tpn-to-extend-service-offering/ From earlier this month....Still expanding!!
If anyone needs reminding...Half year revenue grew by £85M....classic case of getting over excited from growth & not controlling working capital....new management WILL take care of this....New contracts being signed & expanded.....this is a MAJOR British brand in an expanding marker...a few days of minnow trades will be irrelevant in a few weeks
My advice would be to ride this out. ESL is full of billionaire tycoons...Logistics is a growing market with online buying booming & major contracts being signed/expanded. ESL will be prosperous in the coming years. This one-off impairment is exactly that, a one-off.
Inventory up 1.5M - This should translate into an additional 3.25M revenue at current gross profit margin of c60%. Assuming inventory levels are being well managed then we could all be totally surprised of revenue increase in H2!!
DBAY injected £80m in DEC 19 for 51% of business. This was considered a decent discount at the time but had no choice but to accept. Tinkler & Institutions knew the financial implications at the time valuing the company at £160M
You'd have to say it's a fairly disappointing update - It's obvious to see there is, currently, no real prosperous brand apart from ST.
-Roots revenue decline of 31% was much higher than I expected - not sure where they go from here as that seems a vast drop?!
-Life sciences not really moving anywhere, despite the board claiming yet again that progress is being made.
- C&L healthy growth but estimates of c£300k for the full year isn't exactly ground breaking.
It feels for me as though NUthing has built up some pressure to perform well from the initial launch - I'm impressed with the product & can see it fitting in the SD demographic (fingers crossed). It's fair to say this should be the last loss making H1 - NUthing should ensure consistent revenue/cash all year round.